Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo

Keyphrases

• Small Interfering RNA (siRNA) 100%
• Nanoparticles 100%
• Human Glioblastoma 100%
• Glioblastoma 50%
• Glioblastoma Cells 50%
• NKCC1 50%
• Cell Death 33%
• Survivin 33%
• Roundabout 33%
• Anti-glioblastoma 33%
• Tumor Burden 16%
• Polymeric Nanoparticles 16%
• Potential Side Effects 16%
• Novel Treatments 16%
• Nanoparticle Formulation 16%
• Healthy Cells 16%
• Combination Therapy 16%
• Intratumoral Administration 16%
• Biodegradable Polymers 16%
• Platform Technology 16%
• Cancer Cell Migration 16%
• Survivin siRNA 16%
• Glioblastoma Survival 16%
• Bioreducible 16%
• Multimodal Therapeutics 16%
• Yes-associated Protein 1 (YAP1) 16%
• Biodegradable Particles 16%
• Single Nanoparticle 16%
• Non-viral Delivery 16%
• EGFR siRNA 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Small Interfering RNA 100%
• Malignant Neoplasm 100%
• Nanoparticle 100%
• Glioblastoma 100%
• Survivin 30%
• Epidermal Growth Factor Receptor 30%
• Side Effect 10%
• Neoplasm 10%
• Combination Therapy 10%